{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T06:53:04Z","timestamp":1791701584009,"version":"4.3.4"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1,15]]},"DOI":"10.2146\/ajhp140045","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T13:42:12Z","timestamp":1419946932000},"page":"101-110","source":"Crossref","is-referenced-by-count":14,"title":["Trametinib: A novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma"],"prefix":"10.1093","volume":"72","author":[{"given":"Clement","family":"Chung","sequence":"first","affiliation":[{"name":"Harris Health System, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Reilly","sequence":"additional","affiliation":[{"name":"Harris Health System, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041008210276600_b1-0720101","unstructured":"American Cancer Society. Cancer facts and figures 2014. www.cancer.gov\/cancertopics\/types\/melanoma (accessed 2014 Apr 8)."},{"key":"key\n\t\t\t\t2019041008210276600_b2-0720101","first-page":"1646","article-title":"Cutaneous melanoma","volume-title":"DeVita, Hellman, and Rosenberg\u2019s cancer: principles and practice of oncology","author":"Slingluff","year":"2001"},{"key":"key\n\t\t\t\t2019041008210276600_b3-0720101","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ctrv.2007.06.004","article-title":"Treatments for metastatic melanoma: synthesis of evidence from randomized trials","volume":"33","author":"Lui","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"key\n\t\t\t\t2019041008210276600_b4-0720101","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.hoc.2009.03.009","article-title":"Melanoma and immunotherapy","volume":"23","author":"Eggermont","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"key\n\t\t\t\t2019041008210276600_b5-0720101","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10555-013-9433-9","article-title":"Targeting MAPK pathway in melanoma therapy","volume":"32","author":"Cheng","year":"2013","journal-title":"Cancer Metastasis Rev"},{"key":"key\n\t\t\t\t2019041008210276600_b6-0720101","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-3163-3-6","article-title":"Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis","volume":"3","author":"Houben","year":"2004","journal-title":"J Carcinog"},{"key":"key\n\t\t\t\t2019041008210276600_b7-0720101","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019041008210276600_b8-0720101","volume-title":"Mekinist (trametinib) prescribing information","year":"2013"},{"key":"key\n\t\t\t\t2019041008210276600_b9-0720101","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019041008210276600_b10-0720101","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogene BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041008210276600_b11-0720101","doi-asserted-by":"crossref","first-page":"2371s","DOI":"10.1158\/1078-0432.CCR-05-2539","article-title":"Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma","volume":"12","author":"Panka","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041008210276600_b12-0720101","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature05661","article-title":"Melanoma biology and new targeted therapy","volume":"445","author":"Gray-Schopfer","year":"2007","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019041008210276600_b13-0720101","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-8722-3-8","article-title":"From basic research to clinical development of MEK1\/2 inhibitors for cancer therapy","volume":"3","author":"Fr\u00e9min","year":"2010","journal-title":"J Hematol Oncol"},{"key":"key\n\t\t\t\t2019041008210276600_b14-0720101","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"key":"key\n\t\t\t\t2019041008210276600_b15-0720101","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008210276600_b16-0720101","doi-asserted-by":"crossref","first-page":"20411","DOI":"10.1073\/pnas.0905833106","article-title":"MEK1 mutations confer resistance to MEK and B-RAF inhibition","volume":"106","author":"Emery","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t2019041008210276600_b17-0720101","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019041008210276600_b18-0720101","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008210276600_b19-0720101","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/jid.2012.63","article-title":"Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF\/MEK inhibition","volume":"132","author":"Gowrishankar","year":"2012","journal-title":"J Invest Dermatol"},{"key":"key\n\t\t\t\t2019041008210276600_b20-0720101","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041008210276600_b21-0720101","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","article-title":"GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition","volume":"17","author":"Gilmartin","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041008210276600_b22-0720101","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmaco-dynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019041008210276600_b23-0720101","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/jcph.115","article-title":"Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer","volume":"53","author":"Cox","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041008210276600_b24-0720101","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019041008210276600_b25-0720101","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008210276600_b26-0720101","unstructured":"ClinicalTrials.gov. A study comparing trametinib and dabrafenib combination therapy to dabrafenib monotherapy in subjects with BRAF-mutant melanoma. http:\/\/clinicaltrials.gov\/show\/NCT01584648 (accessed 2014 Apr 8)."},{"key":"key\n\t\t\t\t2019041008210276600_b27-0720101","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s11864-013-0226-8","article-title":"Update on the targeted therapy of melanoma","volume":"14","author":"Johnson","year":"2013","journal-title":"Curr Treat Options Oncol"},{"key":"key\n\t\t\t\t2019041008210276600_b28-0720101","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008210276600_b29-0720101","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008210276600_b30-0720101","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1078-0432.CCR-11-1344","article-title":"Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1","volume":"18","author":"Arnault","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041008210276600_b31-0720101","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008210276600_b32-0720101","unstructured":"Red Book Online. Trametinib dimethyl-sulfoxide (Mekinist). www.micromedexsolutions.com (accessed 2014 Apr 7)."},{"key":"key\n\t\t\t\t2019041008210276600_b33-0720101","unstructured":"Red Book Online. Dabrafenib mesylate (Tafinlar). www.micromedexsolutions.com (accessed 2014 Apr 7)."},{"key":"key\n\t\t\t\t2019041008210276600_b34-0720101","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/S1470-2045(12)70539-9","article-title":"Which drug, and when, for patients with BRAF-mutant melanoma?","volume":"14","author":"Jang","year":"2013","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019041008210276600_b35-0720101","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.currproblcancer.2011.07.003","article-title":"Melanoma brain metastases: is it time to reassess the bias?","volume":"35","author":"Flanigan","year":"2011","journal-title":"Curr Probl Cancer"},{"key":"key\n\t\t\t\t2019041008210276600_b36-0720101","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1479-5876-10-107","article-title":"Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"key":"key\n\t\t\t\t2019041008210276600_b37-0720101","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: Melanoma. V.4.2013. www.nccn.org (accessed 2014 Jan 1)."},{"key":"key\n\t\t\t\t2019041008210276600_b38-0720101","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJMc1302338","article-title":"Hepatotoxicity with combination of vemurafenib and ipilimumab","volume":"368","author":"Ribas","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008210276600_b39-0720101","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1200\/JCO.2012.45.5568","article-title":"Targeting oncogenic drivers and the immune system in melanoma","volume":"31","author":"McArthur","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041008210276600_b40-0720101","unstructured":"ClinicalTrials.gov. A study of the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib in the adjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection (COMBI-AD). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01682083?term=trametinib&rank=3 (accessed 2014 Jan 3)."},{"key":"key\n\t\t\t\t2019041008210276600_b41-0720101","unstructured":"ClinicalTrials.gov. Study of dabrafenib +\/\u2013 trametinib in combination with ipilimumab for V600E\/K mutation positive metastatic or unresectable melanoma. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01767454?term=trametinib&rank=4 (accessed 2014 Jan 3)."},{"key":"key\n\t\t\t\t2019041008210276600_b42-0720101","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008210276600_b43-0720101","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008210276600_b44-0720101","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041008210276600_b45-0720101","unstructured":"Food and Drug Administration. Pembrolizumab. www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm412861.htm (accessed 2014 Nov 12)."},{"key":"key\n\t\t\t\t2019041008210276600_b46-0720101","unstructured":"ClinicalTrials.gov. Trametinib, fluorouracil, and radiation therapy before surgery in treating patients with stage II\u2013III rectal cancer. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01740648?term=trametinib+and+rectal+cancer&rank=1 (accessed 2014 Jan 3)."},{"key":"key\n\t\t\t\t2019041008210276600_b47-0720101","unstructured":"ClinicalTrials.gov. Trametinib and Akt inhibitor GSK2141795 in treating patients with metastatic triple-negative breast cancer. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01964924?term=trametinib+and+breast+cancer&rank=1 (accessed 2014 Jan 3)."},{"key":"key\n\t\t\t\t2019041008210276600_b48-0720101","unstructured":"ClinicalTrials.gov. A phase IIa study of the MEK inhibitor trametinib monotherapy in the treatment of biliary tract cancers. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01943864?term=trametinib&rank=11 (accessed 2014 Jan 3)."},{"key":"key\n\t\t\t\t2019041008210276600_b49-0720101","unstructured":"ClinicalTrials.gov. Dabrafenib, trametinib, and navitoclax in treating patients with solid tumors that are metastatic or cannot be removed by surgery. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01989585?term=trametinib&rank=12 (accessed 2014 Jan 3)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/72\/2\/101\/28320557\/ajhp0101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T22:59:56Z","timestamp":1566169196000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/72\/2\/101\/5111314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,15]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp140045","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,1,15]]},"published":{"date-parts":[[2015,1,15]]}}}